Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Technology company uses virtual clones to predict breast cancer therapy
March 3rd, 2005
Optimata Ltd. and the Soroka University Medical Center announced the launch of a validation study for the treatment of breast cancer using Optimata's virtual cancer patient technology. The technology creates an in silico "clone" for each patient and predicts how the patient will respond to leading cancer drugs such as Adriamycin, Docetaxel, Paclitaxel, Vinorelbine and Tamoxifen. The goal is to improve the efficacy of breast cancer treatments and to avoid the harsh and toxic treatments that patients often undergo at present, when the schedule of chemotherapy is determined by trial-and-error. "Breast cancer patients currently are...
Source: Women's Health Weekly (2005-03-03)
|
